Novavax gets $1.6B from government to develop coronavirus vaccine
Coronavirus vaccine will likely come in early 2021: Dr. Nicole Saphier
Fox News medical contributor Dr. Nicole Saphier says she’s optimistic America will have many more coronavirus treatment options going into flu season in the fall.
Maryland-based Novavax will receive $1.6 billion through the government's Operation Warp Speed to develop a coronavirus vaccine as early as this year, the publicly traded company announced on Tuesday.
Continue Reading Below
"The pandemic has caused an unprecedented public health crisis, making it more important than ever that industry, government and funding entities join forces to defeat the novel coronavirus together," Novavax President and CEO Stanley C. Erck said in a statement. "We are honored to partner with Operation Warp Speed to move our vaccine candidate forward with extraordinary urgency in the quest to provide vital protection to our nation’s population."
The government money will fund Novavax's late-stage clinical trials of its coronavirus vaccine candidate. Novavax began a Phase 1/2 trial of its vaccine candidate on 130 healthy participants in Australia in May.
Ticker | Security | Last | Change | Change % |
---|---|---|---|---|
NVAX | NOVAVAX INC. | 79.44 | -2.20 | -2.69% |
Novavax will use the $1.6 billion for a Phase 3 trial with up to 30,000 participants in the fall.
WHAT IS NOVAVAX?
"Adding Novavax' candidate to Operation Warp Speed's diverse portfolio of vaccines increases the odds that we will have a safe, effective vaccine as soon as the end of this year,” Health and Human Services Secretary Alex Azar said in a statement. "Today's $1.6 billion investment supports the Novavax candidate, depending on success in clinical trials, all the way through to manufacturing 100 million doses for the American people."